Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SYS6043 With or Without Bevacizumab, With or Without Chemotherapy in Participants With Advanced Solid Tumors

NCT07833735 is registered in ClinicalTrials.gov with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor.

NCT NCT07833735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07833735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SYS6043 With or Without Bevacizumab, With or Without Chemotherapy in Participants With Advanced Solid Tumors
Lead sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
October 15, 2029
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors